Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRXNASDAQ:DXRNYSE:ELMDNASDAQ:INGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$5.86-1.2%$6.57$4.30▼$18.55$152.79M1.3324,722 shs282,241 shsDXRDaxor$8.75-0.5%$7.91$6.55▼$10.00$42.32M-0.135,804 shs2,021 shsELMDElectromed$20.07+0.3%$21.68$13.74▼$35.56$168.31M0.473,341 shs55,783 shsINGNInogen$6.25-3.0%$6.67$5.70▼$13.33$168.04M1.64239,471 shs132,877 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx0.00%-10.67%-7.57%-50.13%-42.55%DXRDaxor0.00%-5.41%+14.23%+9.79%-2.78%ELMDElectromed0.00%-4.20%-6.87%-19.01%+38.22%INGNInogen0.00%-5.16%+2.63%-16.67%-14.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVRXCVRx3.082 of 5 stars3.42.00.00.03.04.20.6DXRDaxor3.9595 of 5 stars3.53.00.00.02.73.30.0ELMDElectromed1.149 of 5 stars2.05.00.00.00.61.70.0INGNInogen4.0779 of 5 stars3.04.00.03.91.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.71Moderate Buy$14.50147.44% UpsideDXRDaxor 3.00Buy$25.00185.71% UpsideELMDElectromed 4.00Strong Buy$38.0089.34% UpsideINGNInogen 2.00Hold$9.5052.00% UpsideCurrent Analyst Ratings BreakdownLatest DXR, INGN, CVRX, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/15/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.004/9/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025CVRXCVRxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/8/2025CVRXCVRxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.003/17/2025DXRDaxorAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.75 ➝ $25.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$52.87M2.89N/AN/A$2.73 per share2.15DXRDaxor$2.13M19.86N/AN/AN/A∞ELMDElectromed$61.44M2.74$0.49 per share41.36$5.10 per share3.94INGNInogen$339.96M0.49N/AN/A$8.79 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$59.97M-$2.18N/AN/AN/A-116.91%-93.06%-51.78%8/4/2025 (Estimated)DXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AELMDElectromed$5.15M$0.7926.76∞N/A11.34%15.71%13.37%N/AINGNInogen-$102.45M-$1.15N/AN/AN/A-15.89%-27.38%-16.77%8/5/2025 (Estimated)Latest DXR, INGN, CVRX, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/ADXRDaxor$0.030.34%N/AN/AN/AELMDElectromedN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx0.6912.0610.23DXRDaxorN/AN/AN/AELMDElectromedN/A5.104.74INGNInogenN/A2.662.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%DXRDaxor1.34%ELMDElectromed40.82%INGNInogen89.94%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%DXRDaxor59.00%ELMDElectromed14.00%INGNInogen1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.07 million21.12 millionOptionableDXRDaxor374.84 million1.98 millionNot OptionableELMDElectromed1608.39 million7.36 millionOptionableINGNInogen1,03026.89 million23.58 millionOptionableDXR, INGN, CVRX, and ELMD HeadlinesRecent News About These CompaniesInogen (INGN) Initiated with Buy Rating by B. Riley Analyst | INGN Stock NewsJune 16 at 5:41 AM | gurufocus.comInogen (INGN) Receives Buy Rating and $14 Target from B. Riley | INGN Stock NewsJune 15 at 9:30 PM | gurufocus.comHere’s Why Brown Capital Management Small Company Fund Sold Inogen (INGN) in Q1June 10, 2025 | insidermonkey.comTwo Sigma Advisers LP Lowers Holdings in Inogen, Inc. (NASDAQ:INGN)June 8, 2025 | marketbeat.comInogen (INGN) Down 0.8% Since Last Earnings Report: Can It Rebound?June 7, 2025 | msn.com46,224 Shares in Inogen, Inc. (NASDAQ:INGN) Purchased by Squarepoint Ops LLCJune 5, 2025 | marketbeat.comMillennium Management LLC Acquires 88,924 Shares of Inogen, Inc. (NASDAQ:INGN)June 5, 2025 | marketbeat.comWith 72% ownership of the shares, Inogen, Inc. (NASDAQ:INGN) is heavily dominated by institutional ownersMay 30, 2025 | finance.yahoo.comHere's Why You Should Add Inogen Stock to Your Portfolio NowMay 28, 2025 | zacks.comZacks.com featured highlights Urban Outfitters, Inogen and Southwest GasMay 28, 2025 | finance.yahoo.com3 Stocks With Upgraded Broker Ratings to Bet on Amid UncertaintiesMay 27, 2025 | zacks.comD. E. Shaw & Co. Inc. Sells 77,489 Shares of Inogen, Inc. (NASDAQ:INGN)May 26, 2025 | marketbeat.comInogen shares upgraded to Buy at Needham, $12 price target setMay 24, 2025 | uk.investing.comInogen (NASDAQ:INGN) Stock Rating Upgraded by Needham & Company LLCMay 24, 2025 | marketbeat.comNeedham Upgrades Inogen (INGN) to BuyMay 23, 2025 | finance.yahoo.comNeedham Upgrades Inogen (INGN)May 23, 2025 | msn.comNeedham Upgrades Inogen (INGN) to BuyMay 23, 2025 | msn.comInogen Upgraded: Analyst Sees Growth, EBITDA BreakthroughMay 22, 2025 | benzinga.comThis United Rentals Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayMay 22, 2025 | benzinga.comInogen Approves 2023 Equity Incentive Plan ExpansionMay 19, 2025 | tipranks.comWhat Makes Inogen (INGN) a New Buy StockMay 16, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, INGN, CVRX, and ELMD Company DescriptionsCVRx NASDAQ:CVRX$5.86 -0.07 (-1.18%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$5.88 +0.01 (+0.26%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Daxor NASDAQ:DXR$8.75 -0.04 (-0.46%) As of 06/13/2025 03:58 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Electromed NYSE:ELMD$20.07 +0.06 (+0.30%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$20.08 +0.01 (+0.05%) As of 06/13/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Inogen NASDAQ:INGN$6.25 -0.19 (-2.95%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.37 +0.12 (+1.92%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
